In addition, pyridoxine disulfide (called pyritinol, a derivative of B6) can be used as a nootropic
That comparison is from the studied FDA-approved products under trial conditions - it's relevant context for understanding why tirzepatide's higher efficacy average might justify its slightly higher price point, but it doesn't predict the gap in any individual patient's results
Furthermore, in another meta-analysis [23], which excluded ELIXA [24] due to fact that lixisenatide is a short-acting GLP-1RA and all participants had acute coronary syndrome, GLP-1RAs were associated with significant reductions in MACE (HR 0.85, 95% CI 0.800.90), cardiovascular death (HR 0.85, 95% CI 0.780.93), stroke (HR 0.81, 95% CI 0.740.90), and myocardial infarction (HR 0.88, 95% CI 0.810.96) (Table 2)
:
2017 Oct 1;186:66-79
- Keep out of reach of children